Holiday Notification: Cayman Chemical will be closed Monday, September 6, 2010, in observance of the Labor Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, September 7, 2010. Thank you for your patience.
Research Area · Diabetes
· See all 100+ product categories
| Item Number | Product | Sizes & Pricing | CAS | Purity | Image | Exclusive | Introduction Date | Mojo | Plain Text Name | Synonyms | Keywords |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10010132 |
15- |
- | ≥98% (isomer mixture) |
|
2008-06-09 | 41.442289748312 | 15-deoxy-12-14-prostaglandin-j2-2-glycerol-ester | 15-deoxy-Δ12,14-PGJ2-2-glycerol ester | PPARgamma PPAR.gamma. PPARg PGD2 PGJ2 lipolysis prostaglandins adipocyte endocannabinoid metabolism diabetes obesity nuclear receptors COX-2 COX2 2-AG 2AG | ||
| 13265 |
4- |
1011268-23-7 | ≥98% |
|
✓ | 2010-06-16 | 0E-12 | 4-hydroxy-nonenal-alkyne | Click Tag™ 4-HNE alkyne | lipids peroxidation inflammation neurodegeneration atherosclerosis diabetes cancers click chemistry Click Tag™ 4-HNEs alkynes IT | |
| 10008492 | Adipose Triglyceride Lipase Blocking Peptide | - | 2006-06-27 | 16.096408839779 | adipose-triglyceride-lipase-blocking-peptide | ATGL; TG-hydrolase inducible PLA2-ζ; Desnutrin | antibodies western blotting blots signaling signalling IHC WB formalin immunohistochemistry controls peptides proteins triglycerides energy storage mammalian adipose tissues caloric excess enzymes mobilization fatty acids catalyzes triacylglycerols diacylglycerols inhibition acylhydrolase activity diabetics pathology lung skeletal muscles testis heart brain kidney cells brown fat livers murine mouse macrophages HepG2 atherosclerosis | ||||
| 10006409 | Adipose Triglyceride Lipase Polyclonal Antibody | - |
|
2005-11-23 | 24.063149171270 | adipose-triglyceride-lipase-polyclonal-antibody | Phospholipase A2ζ; Desnutrin; ATGL | antibodies antisera antiserum WB western blots blotting IHC immunohistochemistry triglycerides energy storage mammalian adipose tissues caloric excess enzymes mobilization fatty acids catalyzes triacylglycerols diacylglycerols inhibition acylhydrolase activity diabetics pathology lung skeletal muscles testis heart brain kidney cells brown fat livers murine mouse macrophages HepG2 atherosclerosis immunoblotting | |||
| 10010241 | AICAR | 2627-69-2 | >98% |
|
2008-02-25 | 245.893950276243 | aicar | NSC 105823; Acadesine; AICA Riboside | AMPK lipids metabolism glucose fatty acids sterol HMG-CoA reductases inflammation cytokine iNOS COX-2 MnSOD glia macrophages TNF-.alpha. IL-1.beta. IL-6 aminoimidazole carboxamide ribonucleotide | ||
| 10010332 |
AMP- |
216758-20-2 | ≥95% |
|
✓ | 2008-11-21 | 5.983701657458 | amp-deoxynojirimycin | Adamantane-pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl)-Deoxynojirimycin; AMP-dNM | inhibitors inhibits inhibition ceramides lipids glycolipids glucosylceramide synthase glucosylceramidase β-glucosidase 2 glucosidase sphingomyelin deoxynorjirimycin nojirimycin inflammation antiinflammatory anit-inflammatory hapten colitis insulin sensitivity resistance SREBPs sterol genes expression cholesterol HepG2 cells | |
| 13523 |
Apelin- |
217082-58-1 | ≥95% |
|
2010-06-29 | 0E-12 | apelin-13 | ligands APJ receptors central nervous system cardiovascular functions fluid homeostasis neurosciences hypertension diabetes metabolic syndrome insulin HIV aids | |||
| 10010266 |
BAY- |
19542-67-7 | ≥98% |
|
2008-07-25 | 37.916053670087 | bay-11-7082 | inhibitors inhibits inhibition NFkB NF-.kappa.B NF-kB NF-kappaB TNF.alpha. TNFa TNFalpha I.kappa.B-.alpha. IkB-a IkappaB-alpha inflammation cytokine cell adhesion ICAM-1 ICAM1 VCAM-1 VCAM1 E-selection Eselection Bay 11-7082 BAY-117821 Bay117082 BAY 117821 | |||
| 10009145 | Bezafibrate | 41859-67-0 | >98% |
|
2007-08-02 | 11.961077348066 | bezafibrate | Difaterol; Bezatrol; Bezalip; BM 15075; Benzofibrate | PPAR PPAR.alpha. PPAR.delta. PPAR.gamma. agonist Pan-PPAR cholesterol atherosclerosis metabolic syndromes LDL HDL proliferator-activated receptors diabetes low-density high-density lipoproteins atherosclerosis cardiovascular PPARa PPARd PPARg endocrinology fibrate | ||
| 71748 | CAY10415 Exclusive | 146062-49-9 | ≥98% |
|
✓ | 2008-07-28 | 110.521892265193 | cay10415 | thiazolidinediones TZDs PPARgamma PPARg PPAR.gamma. antidiabetic anti-diabetic insulin blood glucose resistance lipogenesis peroxisome proliferators activated receptors | ||
| 10007875 | CAY10499 Exclusive | 359714-55-9 | >98% |
|
✓ | 2006-07-25 | 23.061418047882 | cay10499 | obesity lipases diabetes triglycerides diacylglycerol inhibitors steroidogenesis spermatogenesis atherosclerosis HSL hormone sensitive endocrinology | ||
| 10009079 | CAY10506 Exclusive | 292615-75-9 | ≥98% |
|
✓ | 2008-11-17 | 65.103591160220 | cay10506 | diabetes glucose metabolism TZDs PPARγ agonists α-lipoic acids anti-diabetic | ||
| 10009536 | CAY10512 | 139141-12-1 | >97% |
|
2007-07-18 | 12.972464088398 | cay10512 | analogs resveratrol nuclear factors NFkB NF-.kappa.B immunity inflammation stress growth apoptosis trans-stilbene activation cancers NF-kB inhibition inhibtors inhibits atherosclerosis | |||
| 10009017 | CAY10514 | 868526-38-9 | >98% |
|
2007-01-24 | 3.903121546961 | cay10514 | Methyl-8-hydroxy-8-(2-pentyl-oxyphenyl)-oct-5-ynoate | peroxisome proliferator-activated receptors aromatics analogs 8-HETEs 8S-HETE 8(S)-HETE agonists PPARa PPARalpha PPAR.alpha. PPARg PPARgamma PPAR.gamma.atherosclerosis | ||
| 10012562 | CAY10566 | 944808-88-2 | ≥98% |
|
2009-01-07 | 11.287292817680 | cay10566 | SCD1 long chain fatty acids monounsaturated type 2 two diabetes dyslipidemia obesity | |||
| 10008846 | CAY10573 Exclusive | 853652-40-1 | ≥98% |
|
✓ | 2009-02-02 | 69.117906691221 | cay10573 | PPARs rosiglitazone diabetes PPARα PPARδ PPARγ | ||
| 13143 | CAY10587 Exclusive | 1082058-99-8 | ≥98% |
|
✓ | 2009-07-02 | 11.520883977900 | cay10587 | free fatty acid receptor1 FFA1 GPR40 pancreatic b-cells glucose insulin diabetes obesity metabolic syndrome receptors | ||
| 13282 | CAY10599 Exclusive | 1143573-33-4 | ≥98% |
|
✓ | 2009-07-21 | 79.739828115408 | cay10599 | thiazolidinedione PPARs PPARγ agonist rosiglitazones BRL 49653 BRL49653 BRL-49653 diabetes TZDs | ||
| 10009796 | CAY10602 | 374922-43-7 | ≥95% |
|
2009-07-15 | 11.461740331491 | cay10602 | SIRT1 Activator 1 SIRTs sirtuins inflammation deacetylase NF-kB NFkB NF-κB NFκB | |||
| 10010250 | Cellular Retinol Binding Protein 7 Polyclonal Antibody | - |
|
2007-10-16 | 5.420530386740 | cellular-retinol-binding-protein-7-polyclonal-antibody | Retinoid Binding Protein 7; cRBP7; RET7; Cellular Retinol Acid-Binding Protein IV | western blots WB ICC immunocytochemistry micronutrient cell growth differentiation CRBPs RBP4 RBP7 atherosclerosis blotting immunoblotting IHC immunohistochemistry | |||
| 10007171 | Cetaben | 55986-43-1 | >98% |
|
2005-11-11 | 8.904295580110 | cetaben | Hexadecylamino-p-amino Benzoic Acid | clofibrate peroxisomes proliferator-activated receptors PPARalpha PPAR.alpha.-independent hypolipidemic activity reduces reduction serums triglycerides cholesterols concentrations peroxisomal enzymes inhibits synthesis hepatoma HepG2 cells reversible changes Golgi morphology blocked esters inhibitors fibrates class atherosclerosis endocrinology | ||
| 10011286 | Chenodeoxycholic Acid | 474-25-9 | ≥95% |
|
2009-02-25 | 0.099447513812 | chenodeoxycholic-acid | Ulmenide; Kebilis; Anthropodeoxycholic Acid; Hekbilin; Fluibil; CDCA | FXR biles acids cholesterol oxidative stress glutathione cancers atherosclerosis diabetes hyperlipidemia CDA | ||
| 10006790 | ChREBP Blocking Peptide | - | 2007-06-06 | 0E-12 | chrebp-blocking-peptide | WBSCR14; Carbohydrate Response Element-binding Protein | proteins diseases WB western blots blotting ICC immunocytochemistry transcription factors nutrients hormonal regulations genes encoding enzymes glucose metabolisms lipogenesis pathways domains nuclear localization signals NLS N-terminus polyprolines basic tissues livers kidneys adipose basal cytosols proteins nucleus dephosphorylations mouse fat HepG2 cells | ||||
| 10010060 |
ChREBP Cell- |
- |
|
2007-08-15 | 12.783215469613 | chrebp-cell-based-translocation-assay-kit | Carbohydrate Response Element-Binding Protein Cell-Based Translocation Assay Kit | assays kits transcription factors TFs diabetes nutrients hormones hormonal regulation genes encoding enzymes glucose metabolisms lipogenesis dephosphorylated cytoplasm protein Ser196 nucleus liver obesity tolerance drugs discovery modulators sub-cellular localization ICC immunocytochemical stains staining antibody antibodies DyLightTM Pierce Biotechnology Inc. fluorescence fluorescent fluorometric endocrinology cell-based assay cell based assay cba | |||
| 10009524 | ChREBP DBD (human recombinant) | - | >85% by SDS-PAGE | 2007-04-12 | 1.620372928176 | chrebp-dbd-human-recombinant | GenBank Accession No. BC012925; Carbohydrate Response Element-binding Protein DNA Binding Domain | EMSA electrophoretic mobility shift assays transcription factors proteins diabetes obesity insulin HLH MLXIPL MIO WBSCR14 endocrinology | |||
| 10009753 | ChREBP DBD Western Ready Control | - | 2007-05-03 | 2.160497237569 | chrebp-dbd-western-ready-control | Carbohydrate Response Element-binding Protein DNA Binding Domain; WS-bHLH; Williams Beuren Syndrome Chromosome Region 14 | WB western blot western blotting Thr666 PP2A carbohydrate response element CRE L-type pyruvate kinase L-PK glucose Ser196 endocrinology | ||||
| 71730 | Ciglitazone | 74772-77-3 | >98% |
|
124.729377197388 | ciglitazone | U-63287; ADD 3878 | nuclear receptors antidiabetic diabetes thiazolidinedione PPAR gamma PPAR.gamma. Peroxisome Proliferator-activated receptors Ligands Binding domains antihyperglycemic atherosclerosis endocrinology | |||
| 700210 | DPP (IV) Inhibitor Screening Assay Kit | - |
|
2009-05-27 | 115.718314917126 | dpp-iv-inhibitor-screening-assay-kit | Dipeptidyl exopeptidases IV DPPIV DPP4 enzymes CD26 cluster of differentiation T-cells activation antigens adenosine deaminase complexing 2 membrane-bound glycoproteins immune regulation signal transduction apoptosis kidneys small intestines placentas humans serums seminal fluids proteolytic derivatives serines X-prolines X-alanines dipeptides N-terminus N-terminal polypeptides growth factors chemokines neuropeptides vasoactive inhibitors inhibits inhibition oral antidiabetic agents glucose homeostasis glucoregulatory hormones glucose-dependent insulinotropics GIP glucagon-like peptide-1 GLP-1 gastric therapeutics Type 2 tumors cancers markers neoplasms assays kits measures measurements fluorescences fluorescent fluorogenics substrates Gly-Pro-Aminomethylcoumarin AMC | ||||
| 10011296 |
(E)- |
39025-24-6 | ≥98% |
|
2009-12-03 | 0.471069135434 | -e-guggulsterone | anti-flammatory cancers FXR bile acids LDL cholesterol antiinflammatory atherosclerosis obesity diabetes inflammation farnesoid X receptors guggul trees | |||
| 10008884 | Eicosapentaenoic Acid ethyl ester | - | ≥98% |
|
2009-01-29 | 38.797624309392 | eicosapentaenoic-acid-ethyl-ester | EPA-EE; EPA ethyl ester | fish oils anti-inflammatory anitinflammatory cardiovascular polyunsaturated fatty acids PUFAs EPAs nutrition oxidation competitive inhibitors inhibits inhibition metabolism cholesterol triglycerides insulin resistance adiponectin high fat diet high-fat TNFα | ||
| 10010019 | FABP2 Polyclonal Antibody | - |
|
2007-10-02 | 16.696056098597 | fabp2-polyclonal-antibody | Intestinal Fatty Acid Binding Protein; Fatty Acid Binding Protein 2; I-FABP | WB western blots fatty acids FABPs lipophilic ligands metabolism polymorphism FABP2 IFABP obesity diabetes antibodies antiserum diabetic antisera atherosclerosis endocrinology blotting immunoblotting | |||
| 10007938 | FABP2 (rat recombinant) | - | >95% | 2005-12-16 | 22.467799263351 | fabp2-rat-recombinant | Fatty Acid Binding Protein 2; I-FABP; Intestinal-FABP | protein-only fatty acids binding proteins high affinity constants small endogenous exogenous lipophilic ligands uptake metabolism cellular membranes levels intracellular trafficking substrates modulation enzymes lipid metabolic pathways cells growth differentiation antiparallel .beta. strands barrel cytosolic tissues biomarker myocardial injury infarction atherosclerosis endocrinology | |||
| 10010463 | FABP4 (human recombinant) Western Ready Control | - | 2007-10-23 | 10.947190213101 | fabp4-human-recombinant-western-ready-control | Fatty Acid Binding Protein 4; Adipocyte-FABP; ALBP; FABP4; A-FABP | fatty acids proteins western blots blotting WB binding proteins adipocytes atherosclerosis endocrinology immunoblotting | ||||
| 10005191 | FABP4 (murine recombinant) | - | >95% | 2005-07-27 | 50.747067573310 | fabp4-murine-recombinant | Adipocyte-FABP; ALBP; Fatty Acid Binding Protein 4; A-FABP | protein-only protein-4 endogenous exogenous lipophilic ligands uptake metabolism intracellular trafficking lipid metabolic pathways modulation cell growth differentiation antiparallel .beta. strands barrel fat cells specific facilitate bidirectional flux insulin epinephrine proteins recombinant binding adipocytes fatty acids agonists insulin hyperinsulinemia deficiency afabp adipocytes atherosclerosis endocrinology | |||
| 10004888 |
FMOC- |
35661-60-0 | ≥98% |
|
2010-07-19 | 62.400616942909 | fmoc-l-leucine | FMOC-Leu; NPC 15199; NSC 334290 | peroxisome proliferator-activated proliferator activated receptors activates PPAR PPARg PPAR-g PPARgamma PPAR.gamma. PPAR-gamma PPAR-.gamma. PPARγ PPAR-γ PPAR γ adipocytes differentiation fatty acids uptake glucose metabolism agonist partial insulin resistance diabetes adipogenesis NPC15199 NSC334290 NPC-15199 NSC-334290 | ||
| 13068 | Fucoxanthin | 3351-86-8 | ≥98 |
|
2010-01-29 | 60.796642111725 | fucoxanthin | α-Carotene | carotenoids algae white adipose tissues WAT obesity weight gain uncoupling proteins 1 UCP1 thermogenesis diabetes type 2 hyperinsulinemia glucose insulin all-trans | ||
| 10010622 | Genipin | 6902-77-8 | >98% |
|
2008-05-09 | 150.674033149171 | genipin | (+)-Genipin | obesity diabeties glucose insulin mitochondria UCP2 pancreatic .beta. cells anti-inflammatory antiinflammatory angiogenesis inhibitors inhibits inhibition uncoupling proteins 2 un-coupling angiogenesis apotosis diabetes inflammation metabolism obesity | ||
| 10009582 | Glucose Assay Kit | - |
|
2007-06-11 | 190.436032144650 | glucose-assay-kit | assays kits monosaccharides simple sugars carbohydrates blood stream energy cells hyperglycemia hypoglycemia Diabetes mellitus oxidase-peroxide d-gluconolactone delta-gluconolactone .delta.-gluconolactone plasma serum urine endocrinology | ||||
| 10007206 | GPR40 Blocking Peptide | - | 2007-04-12 | 2.448784530387 | gpr40-blocking-peptide | immunohistochemistry peptide insulin diabetes breast cancer | |||||
| 10007205 | GPR40 Polyclonal Antibody | - | 2007-04-04 | 9.710902394107 | gpr40-polyclonal-antibody | Free Fatty Acid Receptor; FFAR1; G Protein-Coupled Receptor 40 | immunohistochemistry antibody insulin diabetes breast cancer endocrinology IHC | ||||
| 10009374 |
GSK3β (Phospho- |
- | 2006-11-13 | 17.389392265193 | gsk3-phospho-ser9-polyclonal-antibody | Glycogen Synthase Kinase 3β | antibodies proteins diseases antibodies antisera antiserum WB western blots blotting serine/threonine kinases regulation regulates signaling pathways GSK3a GSK3alpha GSK3.alpha. GSK3b GSK3beta inhibitors inhibition inhibits insulin Wnt Ser9 phosphorylation phospho-specific immunoblotting | ||||
| 10008907 | GW 9508 | 885101-89-3 | >98% |
|
2007-05-14 | 21.412969613259 | gw-9508 | agonists GPR40 GPR120 G protein receptors fatty acid glucose insulin MIN6 coupled endocrinology GW9508 | |||
| 10011211 | GW 9578 Exclusive | 247923-29-1 | >98% |
|
✓ | 2008-05-23 | 41.644871923656 | gw-9578 | atherosclerosis PPAR.alpha. PPARalpha PPARa LDLs lipids nuclear receptors fibrates diabetes obesity peroxisome perliforetior-activated | ||
| 10010559 |
HA- |
203911-27-7 | ≥98% |
|
2008-09-03 | 30.874281767956 | ha-1077-hydrochloride | Eril; Fasudil (hydrochloride) | protein kinase inhibitors inhibits inhibition ROCK-II ROCKII PRK2 MSK1 MAPKAP-K1b vasodilation hypertension diabetes renal nephropathy cancers | ||
| 10010324 | Harmine | 442-51-3 | >98% |
|
2007-11-07 | 40.821878453039 | harmine | metabolic syndromes obesity diabetes PPAR.gamma. insulin sensitivity metabolism .beta.-carboline b-carboline alkaloids hyperglycemia signalling pathway inflammatory gene expression endocrinology | |||
| 500340 | Human Serum Albumin EIA Kit | - |
|
2009-07-16 | 84.208135359116 | human-serum-albumin-eia-kit | Human Serum Albumin EIA Kit; HSA ELISA Kit | solid plates EIAs ELISAs enzymes immunoassays kits measures measurement renal kidneys blood proteins serums osmotic pressure buffering pH hormones fatty acids transports transportation microaluminuria macroalbuminuria disease non-diabetic nephropathy cardiovascular morbidity mortality creatinine assays | |||
| 10010676 |
Hydrochlorothiazide- |
- | ≥99% deuterated product |
|
2009-05-02 | 0E-12 | hydrochlorothiazide-d2-15n2 | 58-93-5 8049-49-8 125727-50-6 edema hypertension diabetes deuterated deuterium | |||
| 16833 | Lisinopril | 76547-98-3 | ≥98% |
|
2009-03-09 | 2.077348066299 | lisinopril | MK 522; MK 521 | inhibitors inhibits inhibition angiotensin I II ACE endothelin 1 nitric oxide renin hypertension diabetes | ||
| 10010785 |
(±)- |
6493-06-7 | ≥98% |
|
2009-09-18 | 16.398646408840 | -lisofylline | CT-1501R; BL 194; LSF | pentoxifylline phosphatidic acids shock sepsis antiinflammatory anti-inflammatory insulin diabetes IL-12 IL-12 inhibits inhibitions inhibitors IFN-γ IFNγ β-cell cell 39476-38-5 151852-35-3 | ||
| 10010236 |
ML- |
105637-50-1 | ≥98% |
|
2008-01-21 | 1.434254143646 | ml-9 | PKB Akt inhibitors inhibits inhibition serine/threonine kinase PKA P90S6 MAP kinases cancers anti-cancers insulin glucose transports calcium channels calmodulin intracellular smooth muscles asthma | |||
| 10009661 |
N- |
- | >95% |
|
2008-04-23 | 0E-12 | n-octadecyl-n-propyl-sulfamide | PPAR.alpha. PPARa PPARalpha OEA satiety obesity metabolism food intake triglyceride lipids activators appetite suppression | |||
| 600240 | Orexin 1 Receptor STEP Reporter Assay Kit (Luminescence) New | - |
|
2010-03-31 | 0E-12 | orexin-1-receptor-step-reporter-assay-kit-luminescence | OX1R | hypercretins 1 orexins 2 A orexin-2 systems regulates regulator sleep wake cycles feeding cardiovascular autonomic hypothalamic neuropeptides Orexins A Orexins B gut hormones secretions hypothalamus midbrains brainstems G protein-coupled receptors GPCRs orexin-1 OX1R orexin-2 OX2R orexin-A orexin-B sleep disorders narcolepsy humans animals rodents energy homeostasis pain stress antagonists drugs addictions withdrawals therapeutics obesity Surface transfection expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated luminescent secretory alkaline phosphatases SEAP signal transduction cascades culture medium luminescence-based high throughput screening screens agonists | |||
| 600250 | Orexin 2 Receptor STEP Reporter Assay Kit (Luminescence) New | - |
|
2010-03-31 | 0E-12 | orexin-2-receptor-step-reporter-assay-kit-luminescence | OX2R | hypercretins 1 orexin 2 systems regulates regulator sleep wake cycles feeding cardiovascular autonomic hypothalamic neuropeptides Orexins A Orexins B gut hormones secretions hypothalamus midbrains brainstems G protein-coupled receptors GPCRs orexin-1 OX1R orexin-2 OX2R orexin-A orexin-B sleep disorders narcolepsy humans animals rodents energy homeostasis pain stress antagonists drugs addictions withdrawals therapeutics obesity Surface transfection and expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated luminescent secretory alkaline phosphatases SEAP signal transduction cascades culture medium luminescence-based high throughput screening screens agonists | |||
| 13804 | OU749 New | 519170-13-9 | ≥95% |
|
2010-07-20 | 0E-12 | ou749 | γ-Glutamyl transferases γ-glutamyl transpeptidases glutathione markers liver dysfunction alcohol abuses biomarkers diabetes cardiovascular diseases cancers acivicin | |||
| 10010374 |
p38 MAPK (Phospho- |
- |
|
2007-09-17 | 3.287292817679 | p38-mapk-phospho-thr180-tyr182-cell-based-phosphorylation-translocation-assay-kit | phosphorylation kits assays enzymes diseases asthma autoimmunity stress response nervous system fluorescence fluorescent fluorometric | ||||
| 10218 | PCSK9 Monoclonal Antibody (Clone 15A6) | - |
|
2008-10-29 | 20.020184162063 | pcsk9-monoclonal-antibody-clone-15a6 | Proprotein Convertase Subtilisin Kexin 9; NARC-1 | antibodies proproteins serine protease lipoproteins LDLs low density neural apoptosis-regulated convertase 1 blotting ligands western immunoblotting WB blots | |||
| 10004943 | PEPCK Polyclonal Antibody | - | 2005-08-03 | 27.545668508287 | pepck-polyclonal-antibody | Phosphoenolpyruvate carboxykinase; PEPCK-c; Pck1 | proteins antibodies antisera antiserum WB western blots blotting hormones regulates enzymes steps gluconeogenesis catalyzing conversions oxaloacetate phosphoenolpyruvate mRNA liver kidney cortex white adipose tissue brown fat mammary gland lactation small intestine non-insulin-dependent diabetes mellitus streptozotocin-induced elevated activity isozymes cytosolic mitochondrial murine mouse rat endocrinology immunoblotting | ||||
| 301707 |
PGC- |
- | 2006-07-25 | 13.382928176796 | pgc-1-blocking-peptide | antibodies western blotting blots signaling signalling IHC WB formalin immunohistochemistry controls peptides proteins diseases proteins peroxisomes receptors gamma .gamma. PGC-1.beta. PGC-1.alpha. PRC N- C-terminus inducible transcriptional nuclear energy hepatic gluconeogenesis cholesterol homeostasis activates oxidative metabolisms tissues kidneys heart brown adipose skeletal muscles metabolic disorders type II 2 diabetes obesity | |||||
| 101707 |
PGC- |
- |
|
2005-10-12 | 33.914053239578 | pgc-1-polyclonal-antibody | PPARγ Coactivator 1; Peroxisome Proliferator-activated Receptor γ Coactivator 1 | atherosclerosis proteins diseases antibodies antisera antiserum WB western blots blotting IHC immunohistochemistry peroxisomes receptors gamma .gamma. PGC-1.beta. PGC-1.alpha. PRC N- C-terminus inducible transcriptional nuclear energy hepatic gluconeogenesis cholesterol homeostasis activates oxidative metabolisms tissues kidneys heart brown adipose skeletal muscles metabolic disorders type II 2 diabetes obesity endocrinology immunoblotting | |||
| 10009088 | PPARα LBD (human recombinant) | - | >90% | 2006-09-13 | 12.125559392264 | ppar-lbd-human-recombinant | Peroxisome Proliferator-activated Receptor α Ligand Binding Domain | receptors PPAR.alpha.1 PPAR.alpha.2 PPARa1 PPARa2 Proteins Ligands domains PPAR's Ligand-activated transcription factors atherosclerosis endocrinology PPARalpha | |||
| 61700 | PPARγ FL (human recombinant from E. coli) | - | >90% by SDS-PAGE | 2007-01-10 | 13.623030781373 | ppar-fl-human-recombinant-from-e-coli | Peroxisome Proliferator-activated Receptor γ Full Length (human recombinant) | proteins binding enzymes PPAR.gamma. PPARgamma diseases obesity diabetes atherosclerosis cancers endocrinology | |||
| 10009987 | PPARγ FL (human recombinant from Sf21 cells) | - | >80% by SDS-PAGE | 2007-06-15 | 17.833683241252 | ppar-fl-human-recombinant-from-sf21-cells | Peroxisome Proliferator-activated Receptor γ Full Length (human recombinant from Sf21 cells) | proteins binding enzymes PPAR.gamma. PPARgamma diseases obesity diabetes atherosclerosis cancers endocrinology | |||
| 10007685 |
PPARγ FP- |
- |
|
2009-07-16 | 60.499944751381 | ppar-fp-based-ligand-screening-assay-kit-green | Peroxisome Proliferator-activated Receptor γ FP-Based Ligand Screening Assay Kit - Green | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARgamma PPAR.gamma. PPARg PPARγ PPAR-γ PPAR-gamma gamma g γ .gamma. PPAR-.gamma. PPAR-g kits assys atherosclerosis TF diabetes drugs discovery discover endocrinology high throughput screens screening inflammations inhibitors inhibits inhibition metabolic syndromes metabolism nuclear receptors fluorescence FP-based FP based base ligands probes proteins isoforms γ1 γ2 γ-1 γ-2 1 2 adipose tissues colon immune systems retinas adipogenesis cells cellular differentiation insulin sensitization cancers fatty acids FAAH arachdionic 15-deoxy-DELTA12,14-prostaglandin 15-deoxy-DELTA12,14-PGs 15-deoxy-DELTA12,14-PGJ2 15 deoxy DELTA 12,14 PGs prostaglandins PGJ2 15-deoxy-Δ12,14-PGs 15-deoxy-Δ12,14-prostaglandins 15-deoxy-Δ12,14-PGJ2 15-deoxy-D12,14-prostaglandins 15-deoxy-D12,14-PGs 15-deoxy-D12,14-PGJ2 15-deoxy-.DELTA.12,14-prostaglandins 15-deoxy-.DELTA.12,14-PGs 15-deoxy-.DELTA.12,14-PGJ2 J2 thiazolidinediones TZD pioglitazone rosiglitazone agonists hyperglycemia hyperinsulinemia hypertriglyceridemia types 2 antidiabetics diabetes oral antagonists | |||
| 10007941 | PPARγ LBD (human recombinant) | - | >90% | 2006-03-16 | 24.550812943962 | ppar-lbd-human-recombinant | Peroxisome Proliferator-activated Receptor γ Ligand Binding Domain | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARgamma PPAR.gamma. PPARg PPARγ PPAR-γ PPAR-gamma gamma g γ .gamma. PPAR-.gamma. PPAR-g recombinant proteins atherosclerosis diabetes endocrinology genes regulations metabolic syndrome nuclear receptors obese obesity PPAR proteins biochemistry hexahistidine-tagged tagged hexahistidine HIS-tag HIS-tagged HIS N-terminal PPARalpha PPAR.alpha. PPARα PPAR-alpha PPAR-.alpha. PPAR-α PPAR-delta PPAR-.delta. PPAR-δ PPARdelta PPAR.delta. PPARδ hNUC1 FAAR pathology diseases cancers domains LBD ligand binds binding DNA DBD RXR acid-like acid like heterodimerization thiazolidinedione rosiglitazone piolitazone insulin type II E. coli coomassie stains staining western blots blotting immunoblotting WB fluorescent | |||
| 10006247 | PPARδ Blocking Peptide | - | >70% | 2004-11-09 | 4.264530386740 | ppar-blocking-peptide | PPARβ; Peroxisome Proliferator-activated Receptor δ; NR1C2 | controls peptides western blots WB immunoblotting antibodies receptors PPARbeta PPAR.beta. lipid metabolism obesity special:month specialdiscount:15 specialstart:2008-02-01 specialend:2008-02-29 | |||
| 10007451 | PPARδ (human recombinant) | - | >95% | 2005-07-29 | 9.948187845304 | ppar-human-recombinant | PPARβ; Peroxisome Proliferative Activated Receptor δ; Nuclear Hormone Receptor 1; NUC1; FAAR | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARdelta PPAR.delta. PPARd PPARδ PPAR-δ PPAR-delta delta .delta. δ PPAR-.delta. PPAR-d recombinant proteins human atherosclerosis cancers EMSA electrophoretic mobility shift assays endocrinology fluorescence metabolic syndrome nuclear obese obesity biochemistry transcription factors members retionic acids genes expression developments baculovirus Sf21 heterodimerize subtypes hNUC1 FAAR ubiquitously tissues mediator embryo implantation overexpression systems gels coomassie stains staining western blots WB immunoblotting 10006914 | |||
| 101720 | PPARδ Polyclonal Antibody | - |
|
2004-11-05 | 15.819088397790 | ppar-polyclonal-antibody | Nuclear Hormone Receptor 1; NUC1; FAAR; PPARβ | PPAR.delta. PPAR.beta. PPARbeta peroxisome proliferator-activated receptors PPARdelta antibodies antisera nuclear receptors antiserum western blots blotting WB ICC immunocytochemistry IHC immunohistochemistry atherosclerosis endocrinology immunoblotting | |||
| 13000 | Pterostilbene | 537-42-8 | ≥98% |
|
2009-09-09 | 13.886543014995 | pterostilbene | 3',5'-Dimethoxy-4-Stilbenol; trans-3,5-Dimethoxy-4'-Hydroxystilbene | resveratrol blueberries antioxidant PGE2 prostaglandins E2 cells proliferation ERK1/2 ERK 1/2 p38 MAPK PI3K/Akt NF-kB NFkB NF-κB NFκB AP-1 AP1 transcriptional activation cancers inflammation diabetes inflammatory | ||
| 13346 | Rapamycin | 53123-88-9 | ≥98% |
|
2009-10-21 | 38.575802540001 | rapamycin | Sirolimus | immunosuppresssants transplants rejection inhibitors IL-2 lymphocytes B cells T FKBP12 mTOR mTORC1 cancer adipogenesis diabetes tuberous sclerosis cardiovascular diseases | ||
| 13616 |
(R)- |
100324-81-0 | ≥98% |
|
2010-05-27 | 5.797237569061 | -r-lisofylline | (R)-LSF; (-)-Lisofylline | pentoxifylline phosphatidic acid shock sepsis anti-inflammatory IFN-γ IL-12 β-cell insulin diabetes interleukins 12 IL IFN-gamma | ||
| 13300 |
Ro 31- |
113963-68-1 | ≥98% |
|
2009-07-28 | 3.809779005525 | ro-31-6045 | Bisindolylmaleimide V | PKC kinase inhibitors S6K mitogen-stimulated proteins p70 p85 protein kinases C | ||
| 71740 | Rosiglitazone | 122320-73-4 | >98% |
|
343.735160220994 | rosiglitazone | BRL 49653 | BRL49653 BRL-49653 ligands ppar.gamma. ppargamma receptors antagonists antidiabetic nuclear receptors diabetes peroxisome atherosclerosis endocrinology | |||
| 10011343 |
Rosiglitazone- |
- | >99% deuterated product |
|
2009-04-04 | 207.046933701657 | rosiglitazone-d5-maleate | SPI TZDs thiazolinedions PPARg PPAR.gamma. PPARgamma selective ligand insulin resistance anti-inflammatory | |||
| 71742 | Rosiglitazone (potassium salt) | 316371-84-3 | >98% |
|
161.052417127072 | rosiglitazone-potassium-salt | BRL49653 BRL-49653 ligands ppar.gamma. ppargamma receptors antagonists antidiabetic nuclear receptors diabetes peroxisome salts thiazolidinediones atherosclerosis endocrinology | ||||
| 10010247 | SB 415286 | 264218-23-7 | ≥98% |
|
2008-10-29 | 12.089189686924 | sb-415286 | GSK3 GSK-3 PI3K signaling PI3K signalling glycogen synthase inhibitors inhibits inhibition neuron survival glycogen synthesis Chang human liver cells line potent selective sb415286 | |||
| 10007682 | Serum Retinol Binding Protein 4 Blocking Peptide | - | 2007-07-30 | 0E-12 | serum-retinol-binding-protein-4-blocking-peptide | pRBP Blocking Peptide; Plasma Retinol Binding Protein 4 Blocking Peptide; sRBP4 Blocking Peptide | wb western blotting TTR serum type 2 diabetes sRBP plasma SRBP-4 blots proteins serums retinols insulin special:month specialdiscount:15 specialstart:2007-08-01 specialend:2007-09-30 RBP | ||||
| 10007818 | Serum Retinol Binding Protein 4 (human recombinant) | - | >95% | 2006-10-05 | 23.712120165746 | serum-retinol-binding-protein-4-human-recombinant | RBP4; sRBP4 | proteins vitamin A blood mammals .beta.-sheet-rich lipocalins hepatocytes plasma tetrameric transthyretin TTR adipocyte-derived adipocytes signaling type 2 diabetes insulin C-terminal terminus hexahistidine tag endocrinology | |||
| 10007681 | Serum Retinol Binding Protein 4 Polyclonal Antibody Exclusive | - |
|
✓ | 2007-08-03 | 4.897116022099 | serum-retinol-binding-protein-4-polyclonal-antibody | Plasma Retinol Binding Protein 4; pRBP; sRBP4 | vitamin A wb western blotting type 2 diabetes lipocalin TTR transthyretin sRBP4 sRBP-4 proteins adipocytes signals signalling signaling insulin blots retinols serums RBP atherosclerosis endocrinology immunoblotting | ||
| 10009754 | Serum Retinol Binding Protein Western Ready Control Exclusive | - | ✓ | 2008-07-08 | 0.441988950276 | serum-retinol-binding-protein-western-ready-control | sRBP4; RBP4 | proteins C-terminal western blots immunoblotting WB SRBPs hexahistidine His-tag His-tagged insulin resistance tyep 2 diabetes pathogenesis blotting | |||
| 13617 |
(S)- |
100324-80-9 | ≥98% |
|
✓ | 2010-05-27 | 2.898618784530 | -s-lisofylline | (S)-LSF; (+)-Lisofylline | pentoxifyllines phosphatidic acid shock sepsis anti-inflammatory IFN-γ IL-12 β-cell insulin diabetes antiinflammatory inflammatory inflammation inflammed | |
| 10011671 | Soluble Epoxide Hydrolase Inhibitor Screening Assay Kit | - |
|
2009-02-24 | 73.638447513812 | soluble-epoxide-hydrolase-inhibitor-screening-assay-kit | sEH Inhibitor Screening Assay Kit | epoxides hydrolases sEHs inhibits inhibition assays kits fluorescence-based catalyzes hydrolysis exogenous endogenous vicinal diols substrates EETs epoxyeicosatrienoic acids vasodilatory vasodilation anti-inflammatory molecules therapy therapeutics hypertension vascular diseases PHOME (3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester 6-methoxy-2-naphthaldehyde excitation emission wavelengths a/b-hydrolases alpha/beta-hydrolases .alpha./.beta.-hydrolases enzymes homodimers C-terminal C-terminus animals models cyanohydrins cyanide ions | |||
| 10009239 |
SREBP- |
- |
|
2007-04-17 | 27.773281767955 | srebp-2-cell-based-translocation-assay-kit | Sterol Regulatory Element-Binding Protein-2 Cell-Based Translocation Assay Kit | sterol regulatory element binding proteins athersclerosis cholesterols fatty acids triglycerides phospholipids helix-loop-helix HLH transcription factors DyLight Pierce Biotechnology assays fluorescence fluorescent fluorometric cell-based assays cell based assay cba | |||
| 10009749 |
SREBP- |
- | 94 kDa (GST-tagged); 68 kDa (native) | 2007-07-30 | 17.977790055248 | srebp-2-western-ready-control | Sterol Regulatory Element-binding Transcription Factor 2; Sterol Regulatory Element-binding Protein 2; SREBPF2 | WB western blot helix loop bHLH fatty acids genes cholesterol regulatory HMG-CoA tissues E. coli SREBP2 SREBPF-2 transcription factors SREBP 2 atherosclerosis | |||
| 10026 | T0070907 | 313516-66-4 | >98% |
|
92.303651933701 | t0070907 | T-0070907 nuclear receptors antagonist PPARgamma PPAR.gamma. peroxisome proliferator-activated selective selectivity thiazolidinediones TZDs inhibits inhibition inhibitors atherosclerosis endocrinology | ||||
| 10010303 | Triglyceride Assay Kit | - |
|
2007-10-31 | 154.307219152854 | triglyceride-assay-kit | assays kits triglycerides enzymes enzymatic hydrolysis water-insoluble lipids three fatty acids esterified glycerols blood serums lipoproteins chylomicrons very low density VLDLs dietary fats metabolisms energy diagnosis primary secondary hyperlipoproteinemia dyslipidemia triglyceridemia diabetes mellitus nephrosis livers obstruction endocrine colorimetric fluorometric plasmas coupled reaction systems | ||||
| 71750 | Troglitazone | 97322-87-7 | >98% |
|
141.123370165745 | troglitazone | ResulinTM | antidiabetic thiazolidinediones PPAR.gamma. PPARgamma ligands selective peroxisome proliferator-activated receptors diabetes TZD Resulin nuclear receptors atherosclerosis endocrinology | |||
| 10010245 |
U- |
137018-55-4 | ≥98% |
|
2008-07-08 | 0E-12 | u-83836e | PNU-83836E | antioxidant anti-oxidant oxidative injury stress free radicals ischemia diabetes a-tocopherol .alpha.-tocopherol 122003-11-6 | ||
| 700320 | Uric Acid Assay Kit New | - |
|
2010-08-30 | 0E-12 | uric-acid-assay-kit | Urate Assay Kit | kits assays measures measurement acids human purines metabolisms urine serum renal excretion excreted allantoin enzymes urate oxidases uricase genes obesity alcohol consumption hyperuricemia gout kidney stones metabolic syndromes hypertension cardiovascular diseases exercise-induced acute failure hypouricemia | |||
| 10010591 | Wortmannin | 19545-26-7 | ≥98% |
|
2008-11-21 | 36.766139502762 | wortmannin | KY 12420 | phosphoinositide 3-kinase PI3K cells growth differentiations cancers motility inhibitors inhibits inhibition irreversible polo-like kinases PLK1 PLK3 mTOR DNA-PK DNAPK PL4K MLCK p38 MAPK | ||
| 13576 |
YM- |
371942-69-7 | ≥95% |
|
2010-04-14 | 0E-12 | ym-201636 | PIKfyve phosphoinositide kinase PIK zinc finger domains phosphatidylinositol 3-phosphate PI3P PI(3,5)P2 membrane trafficking cytoskeleton inhibitors endosomal trafficking endosomes phagocytosis retrovirus virology adipocytes insulin glucose diabetes YM201636 YM 201636 | |||
| 10009992 | Zeaxanthin | 144-68-3 | ≥98% |
|
2009-02-02 | 25.021215469614 | zeaxanthin | Zeaxanthol; Xanthophyll 3; Anchovyxanthin | carotenoid degeneration AMDs luteins diabetes antioxidant oxidative injury injuries VEGFs macula | ||
| 71800 |
(Z)- |
39025-23-5 | ≥98% |
|
2009-12-01 | 1.714984453480 | -z-guggulsterone | anti flammatory cancers FXR bile acids LDL cholesterol tumors IL-6 STAT3 VEGF Akt | |||
| 700190 |
β- |
- |
|
2009-06-02 | 134.243688503025 | -hydroxybutyrate-ketone-body-assay-kit | β-HB Assay Kit; 3-Hydroxybutyric Acid Assay Kit | .beta.-hydroxybutyrate beta-hydroxybutyrate b-hydroxybutyrate b-HB beta-HB .beta.-HB β-HB 3-hydroxybutyric acids ketones body bodies acetoacetates acetones ketosis lipids metabolisms fasting exercise diets diabetes childhood hypoglycemia corticosteroids growth hormones deficiency intoxication alcohols salicylates organ failure ketoacidosis metabolic acidosis blood serums subclinical glucose diabetic coma hyperosmolar non-ketotic insulin hyperketonemia neurodegenerative diseases inhibits inhibition adipocytes lipolysis plasmas urine assays | |||
| 10007602 |
Δ2- |
93772-82-8 | >98% |
|
2006-01-04 | 1.128397790055 | -2-cis-eicosenoic-acid | .alpha.,.beta.-unsaturated fatty acids a,b-unsaturated synthesis .DELTA.2-trans D2 extracted fresh wateer clams medical medicinal diabetes lipids metabolisms 2-octadecenoic livers blood sugars streptozocin-induced rats | |||
| 10007622 |
Δ2- |
- | >98% |
|
2006-01-04 | 1.128397790055 | -2-trans-eicosenoic-acid | .alpha.,.beta.-unsaturated fatty acids a,b-unsaturated synthesis .DELTA.2-cis D2 medical medicinal diabetes lipids metabolisms 2-octadecenoic livers blood sugars streptozocin-induced rats |
Cayman Chemical Company · 1180 East Ellsworth Road · Ann Arbor, Michigan 48108 · USA
Toll Free: (800) 364-9897 (USA and Canada Only) · Fax: (734) 971-3640
Copyright 2010 Cayman Chemical Company
Quick Search